Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash & Equivalents of $5.5 billion for Q1 2026, up 17.5% year-over-year from $4.7 billion in Q1 2025, and up 8.03% quarter-over-quarter from $5.1 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $5.5 billion for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 17.5% year-over-year to $5.5 billion; the TTM figure through Mar 2026 stood at $5.5 billion (up 17.5% YoY), while the FY2025 annual figure was $5.1 billion, up 11.27% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $5.5 billion, up from $5.1 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $11.1 billion in Q3 2023, with the low at $4.6 billion in Q4 2024.
- The 5-year median for Cash & Equivalents is $7.6 billion (2022), against an average of $7.4 billion.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 54.58% in 2022, then sank 55.93% in 2024.
- Vertex Pharmaceuticals' Cash & Equivalents stood at $10.5 billion in 2022, then retreated by 1.28% to $10.4 billion in 2023, then tumbled by 55.93% to $4.6 billion in 2024, then advanced by 11.27% to $5.1 billion in 2025, then grew by 8.03% to $5.5 billion in 2026.
- Business Quant data shows VRTX's Cash & Equivalents at $5.5 billion in Q1 2026, $5.1 billion in Q4 2025, and $4.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.14 Bn |
| Mar 31, 2026 | 5.49 Bn |
| Dec 31, 2025 | 5.08 Bn |
| Sep 30, 2025 | 4.94 Bn |
| Jun 30, 2025 | 4.97 Bn |
| Mar 31, 2025 | 4.67 Bn |
| Dec 31, 2024 | 4.57 Bn |
| Sep 30, 2024 | 5.24 Bn |
| Jun 30, 2024 | 4.58 Bn |
| Mar 31, 2024 | 9.16 Bn |
| Dec 31, 2023 | 10.37 Bn |
| Sep 30, 2023 | 11.11 Bn |
| Jun 30, 2023 | 10.15 Bn |
| Mar 31, 2023 | 9.29 Bn |
| Dec 31, 2022 | 10.50 Bn |
| Sep 30, 2022 | 9.17 Bn |
| Jun 30, 2022 | 8.70 Bn |
| Mar 31, 2022 | 7.60 Bn |
| Dec 31, 2021 | 6.80 Bn |
| Sep 30, 2021 | 6.28 Bn |